MBL-II-141 | CAS#unknown | BCRP inhibitor

MedKoo Cat#: 464691 | Name: MBL-II-141

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MBL-II-141 is a BCRP inhibitor.

Chemical Structure

MBL-II-141

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 464691

Name: MBL-II-141

CAS#: unknown

Chemical Formula: C28H23BrN2O5

Exact Mass: 546.0790

Molecular Weight: 547.41

Elemental Analysis: C, 61.44; H, 4.24; Br, 14.60; N, 5.12; O, 14.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

MBL-II-141; MBLII-141; MBL II-141; MBL-II141; MBL-II 141; MBLII141; MBL II 141;

IUPAC/Chemical Name

5-((4-bromobenzyl)oxy)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-chromene-2-carboxamide

InChi Key

YOURSKBAKQLDQW-UHFFFAOYSA-N

InChi Code

InChI=1S/C28H23BrN2O5/c1-34-20-9-10-22-21(13-20)18(15-31-22)11-12-30-28(33)26-14-23(32)27-24(3-2-4-25(27)36-26)35-16-17-5-7-19(29)8-6-17/h2-10,13-15,31H,11-12,16H2,1H3,(H,30,33)

SMILES Code

BrC(C=C1)=CC=C1COC2=C(C(C=C(C(NCCC3=CNC4=C3C=C(OC)C=C4)=O)O5)=O)C5=CC=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 547.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hénin E, Honorat M, Guitton J, Di Pietro A, Payen L, Tod M. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor. Biopharm Drug Dispos. 2017 Jul;38(5):351-362. doi: 10.1002/bdd.2069. Epub 2017 Mar 23. PMID: 28207160. 2: Pires ADRA, Lecerf-Schmidt F, Guragossian N, Pazinato J, Gozzi GJ, Winter E, Valdameri G, Veale A, Boumendjel A, Di Pietro A, Pérès B. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2. Eur J Med Chem. 2016 Oct 21;122:291-301. doi: 10.1016/j.ejmech.2016.05.053. Epub 2016 Jun 27. PMID: 27376492. 3: Payen L, Honorat M, Guitton J, Gauthier C, Bouard C, Lecerf-Schmidt F, Peres B, Terreux R, Gervot H, Rioufol C, Boumendjel A, Puisieux A, Di Pietro A. MBL- II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. Oncotarget. 2014 Dec 15;5(23):11957-70. doi: 10.18632/oncotarget.2566. PMID: 25474134; PMCID: PMC4323000. 4: Valdameri G, Genoux-Bastide E, Peres B, Gauthier C, Guitton J, Terreux R, Winnischofer SM, Rocha ME, Boumendjel A, Di Pietro A. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem. 2012 Jan 26;55(2):966-70. doi: 10.1021/jm201404w. Epub 2012 Jan 6. PMID: 22165858.